MeCo Diagnostics is a venture-backed startup that has developed the only clinically validated test to match breast cancer patients to a breakthrough therapy, effectively unlocking a whole new treatment strategy. Our landmark Phase 2 randomized controlled trial revealed the greatest survival benefit ever reported for a targeted therapy in the history of breast oncology: We demonstrated a 62% reduction in risk of recurrence over 9.7 years on average for High MeCo Score patients, while Low MeCo Score patients experienced no benefit. MeCo Diagnostics traces its origins to the oldest observation in cancer biology: tumors often grow stiffer than surrounding tissue, leading to a palpable lump. However, not all cancer cells are responsive to increased tumor stiffness, but those that are become “mechanically conditioned,” akin to deadly, microscopic machines that are programmed to wreak havoc as they spread throughout the body. Fortunately, there is an FDA-approved antifibrotic drug which can be repurposed to deprogram these dangerous cancer cells. This serendipity has empowered us to develop a commercially viable, biomarker-enabled drug repurposing approach that synergizes with conventional neoadjuvant treatment. Our lead asset, the MeCo Score, has been rigorously validated in 4 independent clinical studies of breast cancer comprised of over 4000 patients total, in partnership with oncologists at Cleveland Clinic, George Washington University, University of Arizona, and the Spanish National Cancer Research Center. Moreover, since the MeCo Score matches patients to a generic-emergent drug, the cost of targeted antifibrotic therapy will soon be >10X cheaper than any other form of targeted therapy. Since patients benefit from improved efficacy and payers benefit from reduced treatment costs, we are facilitating a win-win opportunity for healthcare stakeholders. For more information, please reach out.
MeCo Diagnostics的外部链接
5015 Shoreham Pl
US，California，San Diego，92122
Will you also be in SF on April 2nd? Let's chat.
I'm looking forward to attending Biocom California's #ConvergeSummit, an invite-only conference dedicated to advancing human health through the collaboration of life science and technology. If you're also attending, let's catch up. We have a lot of exciting updates to share regarding MeCo Diagnostics co-commercialization strategy and our imminent multinational Phase 2/3 clinical trial.
Our co-founder and CSO Dr. Gus Mouneimne in his lab, discussing our latest research: https://lnkd.in/gu88HpZr
It's surreal that our enabling research for this study began over a decade ago, coinciding with the start of the associated clinical trial conducted by our bold collaborators at CNIO - Spanish National Cancer Research Centre. That serendipity has now culminated in a stunning outcome: Patients with High MeCo Score breast cancer who received a short course of neoadjuvant antifibrotic therapy experienced a remarkable improvement in long-term survival likelihood compared to those who received chemotherapy alone. I never imagined that my graduate research project would blossom quite like this, with profound implications for the health economics of the most common subtype of the most common cancer in the US. https://lnkd.in/gwKGGf3N
Many thanks to Biocom for all of their support this past year! https://lnkd.in/dpqPKG_G
Belated thanks to Biocom California for inviting MeCo Diagnostics co-founder Dr. Gus Mouneimne on a trip to Capitol Hill to meet with Directors of the FDA and CMS. Very encouraging meetings! Stay tuned for some big news... https://lnkd.in/gitvrn2i
Two organizations take the stage in today's ACS NBCRT member organization spotlight: MeCo Diagnostics and The Pink Fund. Thank you for your commitment to the ACS NBCRT!
MeCo Diagnostics was selected to present at the San Diego Innovation Council Showcase hosted by Scripps Research on May 22nd. We hope to see you there! https://lnkd.in/dmAxr5fF
2024 is shaping up to be a major year of progress for MeCo Diagnostics!
What's so cool about Cool Companies, after all? Meet the Class of 2024 - handpicked for their disruptive ideas, innovative technologies, and commitment to driving positive change. These companies are poised to make waves in innovation. ?? Check them out: https://bit.ly/3J3FSsK
Get ready for an unforgettable event with our startups! ?? We can't contain our excitement about everyone joining us! Featuring over 300 speakers, 120 exhibitors, and 50 startups, Festival of Biologics offers you the newest research in the field, unparalleled networking opportunities, and the opportunity to meet innovative startups. We're thrilled to announce the participation of five dynamic startups at our upcoming Festival: MeCo Diagnostics is a venture-backed startup developing predictive biomarker tests to unlock low-cost, low-toxicity targeted therapy for cancer. Our Phase 2 study reveals our first-in-class test matches patients with early-stage luminal breast cancer to a highly effective repurposed therapy that is twice as effective as the best targeted therapy currently available. SonoBac, Inc. is a recent spinout from UCSD and the Salk Institute for Biological Studies and is building a platform to increase biomanufacturing titers across multiple model organisms. Their scalable platform starts with a high throughput screen provided as a service followed by implementation of sonogenetic technology at scale. SonoBac is committed to improving biomanufacturing production titers and is looking to partner with drug developers to implement sonogenetics technology. Scispot (YC S21) is the leading tech stack for modern biotech, designed to transform biotech companies into AI powerhouses. By offering a Gen AI-powered data infrastructure, Scispot has become the go-to toolkit for hundreds of digital biotech firms, providing a solid foundation for their growth. Oterus Biosystems, Inc. biosystems is driven to improve the efficiency of In Vitro Fertilization (IVF). Their platform technology enhances embryo implantation, aiming to increase success rates of IVF, a process often requiring multiple cycles and causing emotional and financial strain. We believe everyone, regardless of socioeconomic background, deserves a chance to build a family. ADVANCED PRENATAL THERAPEUTICS, INC. (APT) has received Breakthrough Medical Device Designation by the US FDA for its novel therapy in development to treat preeclampsia (PE), an unmet need and leading cause of maternal and fetal death worldwide. Don't miss them at Festival of Biologics San Diego! Register now to meet them in person ?? https://lnkd.in/eVJxatT8 #festivalofbiologicsUSA #startups